Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
NASDAQ:MDWD

MediWound Q3 2026 Earnings Date & Estimates

MediWound logo
$12.18 +0.08 (+0.66%)
Closing price 04:00 PM Eastern
Extended Trading
$12.20 +0.02 (+0.12%)
As of 04:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MediWound is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from MediWound in Q3 2026

MediWound is expected to post earnings of -$0.7067 per share on revenue of $6.73 million. In the same quarter a year earlier MediWound reported -$0.24 per share on revenue of $5.43 million. MediWound last reported on August 13, 2026, posting -$0.77 per share and missing the -$0.7617 consensus estimate. MediWound has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.7067
Expected Revenue
$6.73 million
Prior-Year EPS
-$0.24
Prior-Year Revenue
$5.43 million
Expected Revenue Growth
+23.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.77 (Missed by -$0.0083)
Last Quarter Revenue
$3.09 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

MediWound Q3 2026 Earnings FAQ

MediWound (NASDAQ:MDWD) is estimated to report Q3 2026 earnings on Thursday, November 19, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

MediWound's Q3 2026 earnings conference call is scheduled for Thursday, November 19, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect MediWound to post earnings of -$0.7067 per share for Q3 2026.

The consensus revenue estimate for MediWound is $6.73 million for Q3 2026.

MediWound Earnings Headlines

H.C. Wainwright Remains a Buy on Mediwound (MDWD)
October 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MDWD/pressreleases/4930103/hc-wainwright-remains-a-buy-on-mediwound-mdwd/
Analysts Are Bullish on These Healthcare Stocks: Mediwound (MDWD), BridgeBio Pharma (BBIO)
September 25, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/BBIO/pressreleases/4797378/analysts-are-bullish-on-these-healthcare-stocks-mediwound-mdwd-bridgebio-pharma-bbio/
“The crisis that’s emerging now is just the tip of the iceberg,” says Dr. Martin D. Weiss, who has made shocking and accurate predictions for 55 years
Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors.tc pixel
October 22 at 1:00 AM  |  Weiss Ratings (Ad)
MediWound Awarded Additional $3.3 Mln By U.S. Dept Of War; Shares Up
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692989/mediwound-awarded-additional-3-3-mln-by-u-s-dept-of-war-shares-up.aspx
Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)
September 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/why-the-pentagon-keeps-funding-this-small-cap-nasdaq-mdwd-1036563671
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366127/30505/en/mediwound-awarded-additional-3-3-million-from-u-s-department-of-war-to-advance-room-temperature-stable-formulation-of-nexobrid.html
See More MediWound Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediWound? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediWound and other key companies, straight to your email.

About MediWound

MediWound (NASDAQ:MDWD) (NASDAQ: MDWD) is a biotechnology company focused on developing and commercializing innovative therapies for complex wounds. The company’s products are designed to remove damaged tissue, support wound healing and address unmet needs in burn care and chronic wounds.

MediWound’s lead commercial product is NexoBrid, a topical bromelain-based enzymatic treatment used to remove eschar—the dead tissue that can form after severe thermal burns. NexoBrid has received regulatory approvals in multiple markets, including the United States, the European Union and Israel, and is marketed for use in the treatment of deep partial-thickness and full-thickness burns.

The company is also developing EscharEx, an investigational topical treatment intended to enzymatically debride chronic wounds, including venous leg ulcers. MediWound is headquartered in Yavne, Israel, and serves healthcare markets through regulatory approvals, commercial partnerships and distribution arrangements in North America, Europe, Israel and other international markets.

View MediWound Profile
Earnings Tools